Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

ART Safety Considerations in Aging Patients With HIV

Source: State of the ART: Applying Up-to-Date Safety and Tolerability Data to Individualize HIV Care
Hear from experts about their approach to caring for older patients with HIV, including deprescribing ARV and non-ARV medications to address polypharmacy and other geriatric syndromes.
Marta Boffito, MD, PhD, FRCP
Julian Falutz, MD, FRCPC
Released: November 2, 2022

In this episode, hear Marta Boffito, MD, PhD, FRCP, and Julian Falutz, MD, FRCPC, discuss their approach to minimizing antiretroviral (ARV)-related intolerances in older patients with HIV, including:

  • Consequences of polypharmacy
  • Deprescribing ARV and non-ARV medications
  • Complications associated with aging (eg, geriatric syndromes such as falls, frailty, multimorbidity)
  • Mediations to avoid, such as anticholinergic medications, to minimize drug–drug interactions and risk of developing geriatric syndromes

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Information on this Educational Activity

Faculty

Marta Boffito, MD, PhD, FRCP

Consultant Physician/Professor
HIV/Research
Chelsea and Westminster Hospital
Imperial College London
London, United Kingdom

Marta Boffito, MD, PhD, FRCP: consultant/advisor/speaker: Cipla, Gilead Sciences, GlaxoSmithKline, Janssen, Merck Sharpe and Dohme, ViiV Healthcare; researcher: Novavax, Roche, Valneva.
Julian Falutz, MD, FRCPC

Associate Professor of Medicine
Department of Medicine
McGill University School of Medicine
Director
Comprehensive HIV and Aging Initiative
Chronic Viral Illness Service
McGill
Montreal, Quebec, Canada

Julian Falutz, MD, FRCPC:consultant/advisor/speaker: Gilead Sciences, Merck, ViiV Healthcare.

Program Medium

This program has been made available online.

Related Content

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

European pioneers discuss the latest data and guideline recommendations for implementing LA ART into practice, from Clinical Care Options (CCO)

Celia Jonsson-Oldenbuettel, MD, PhD
Program Director person default Tom Stephane De Wit, MD, PhD Eric Florence, MD, PhD Mireia SantaCreu Guerrero, MSN person default Laurence Slama, MD, PhD Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: January 20, 2023 Expired: January 19, 2024
Introduction
Patient Candidacy
Administering LA ART
Clinic Infrastructure
What the Future Holds
Q&A Session

Dr Eric Florence discusses clinic adaptations to promote successful integration of long-acting injectables for HIV in this commentary from Clinical Care Options (CCO)

Eric Florence, MD, PhD Released: January 17, 2023

Listen to expert faculty discuss strategies to promote ART safety and tolerability in aging patients and populations with cardiometabolic toxicities, from Clinical Care Options (CCO)

Marta Boffito, MD, PhD, FRCP Jens D. Lundgren, MD, DMSc Released: January 17, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings